{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:24:41Z","timestamp":1783448681104,"version":"3.55.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of hepatocellular carcinoma (HCC), especially those with unresectable advanced stages. The field has progressed rapidly, and the research hotspots have significantly changed compared to previous years. The study aims to comprehensively review and analyze the development history, knowledge structure, current research focus, and emerging trends in ICIs for HCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Reviews and articles published in English from The Web of Science Core Collection (WoSCC) database from 2014 to 2024 were systemically retrieved. Citespace, VOSviewer, and Bibliometrix R package were used for further bibliometric analysis and visualization for countries, institutions, authors, references, and keywords.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>2,941 records were included for analysis. The literature on ICIs for HCC has continued to grow steadily over the past decade. Three major research centers have emerged: North America, Europe, and East Asia. The Chinese institution has the highest publication volume, but Kudo Masatoshi from Japan has the highest number of publications. At the same time, Richard S. Finn from the United States leads in citations and co-citations. The most prolific journal is \u201cCancers\u201d. The clustering and Timeline view of critical literature and keywords indicated that research on ICIs for HCC is rapidly advancing toward a more evidence-based, personalized, and multimodal approach. Immune evasion mechanisms, predictive biomarkers, and high-quality clinical trials focusing on Novel combination, conversion, and perioperative therapies, including ICIs, are emerging hotspots.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study highlights the groundbreaking advancements of ICIs in treating HCC and shows a trend rapidly advancing towards a more evidence-based, personalized, and multimodal approach. The study updated the current understanding of ICIs in hepatocellular carcinoma and identified vital future directions for research, such as the exploration of mechanisms of immune evasion, developing predictive biomarkers, and combining therapy strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1520055","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:29:16Z","timestamp":1744003756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A bibliometric and visual analysis based on immune checkpoint inhibitors for hepatocellular carcinoma: 2014 \u2013 2024"],"prefix":"10.3389","volume":"16","author":[{"given":"Gao-Min","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Alessandro","year":"2023","journal-title":"Lancet. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA a cancer J. Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/JHC.S436804","article-title":"Immunotherapy efficacy in advanced hepatocellular carcinoma in a diverse and underserved population in the United States","volume":"11","author":"Bteich","year":"2024","journal-title":"J. Hepatocell. Carcinoma"},{"key":"B5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","article-title":"Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection","volume":"81","author":"Carla","year":"2024","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"","journal-title":"Hepatol. Baltim. Md"},{"key":"B8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000531744","article-title":"Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis","volume":"13","author":"Celsa","year":"","journal-title":"Liver Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/jdis-2017-0006","article-title":"Science mapping: a systematic review of the literature","volume":"2","author":"Chen","year":"2017","journal-title":"J. Data Inf. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/asi.21309","article-title":"The structure and dynamics of Co-citation clusters: a multiple-perspective Co-citation analysis","volume":"61","author":"Chen","year":"2010","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1145\/3176349.3176897","article-title":"Visualizing and exploring scientific literature with CiteSpace","author":"Chen","year":"2023","journal-title":"Proc. 2018 Conf. Hum. Inf. Interaction&Retrieval - CHIIR"},{"key":"B12","first-page":"893","article-title":"Standard for diagnosis and treatment of primary liver cancer","volume":"40","year":"2024","journal-title":"J. Clin. Hepatol."},{"key":"B13","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","volume":"80","author":"Ciro","year":"2023"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e16209","DOI":"10.1200\/jco.2024.42.16_suppl.e16209","article-title":"Primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"42","author":"Cui","year":"2024"},{"key":"B15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/JS9.0000000000002043","article-title":"Hepatic arterial infusion chemotherapy-based conversion hepatectomy in responders versus nonresponders with hepatocellular carcinoma: a multicenter cohort study","volume":"111","author":"Deng","year":"2024","journal-title":"Int. J. Surg."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet London, Engl."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","article-title":"Immune checkpoint inhibitors for child-pugh class B advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Enrui","year":"2023","journal-title":"JAMA Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular therapies for HCC: looking outside the box","volume":"72","author":"Faivre","year":"2020","journal-title":"J. hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e12349","DOI":"10.1111\/opn.12349","article-title":"Global scientific research on social participation of older people from 2000 to 2019: a bibliometric analysis","volume":"16","author":"Fu","year":"2021","journal-title":"Int. J. Older People Nurs."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5672","DOI":"10.1097\/JS9.0000000000001752","article-title":"Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study","volume":"110","author":"Jiang","year":"2024","journal-title":"Int. J. Surg. Lond. Engl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"John","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Josep","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-23-1462","article-title":"A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: the LAUNCH study","volume":"29","author":"Kazufumi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Ke-Yu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2024.07.017","article-title":"Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"82","author":"Lau","year":"2024","journal-title":"J. hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"LBA432","DOI":"10.1200\/jco.2024.42.3_suppl.lba432","article-title":"EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization","volume":"42","author":"Lencioni","year":"2024"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1097\/JS9.0000000000001155","article-title":"Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study","volume":"110","author":"Li","year":"2024","journal-title":"Int. J. Surg. Lond. Engl."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1210802","DOI":"10.3389\/fimmu.2023.1210802","article-title":"Bibliometric study of immunotherapy for hepatocellular carcinoma","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1093\/oncolo\/oyad277","article-title":"Prognoses of patients treated with surgical therapy versus continuation of local-plus-systemic therapy following successful down-staging of intermediate-advanced hepatocellular carcinoma: a multicenter real-world study","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"key":"B34","doi-asserted-by":"publisher","first-page":"eadj4857","DOI":"10.1126\/science.adj4857","article-title":"A blueprint for tumor-infiltrating B cells across human cancers","volume":"384","author":"Ma","year":"","journal-title":"Sci. (New York, NY)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1097\/JS9.0000000000001193","article-title":"Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb\/IIIa stage: a propensity score matching study","volume":"110","author":"Ma","year":"","journal-title":"Int. J. Surg. Lond. Engl."},{"key":"B36","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2468-1253(23)00147-4","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice","volume":"8","author":"Matthias","year":"2023","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.annonc.2024.03.005","article-title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","volume":"35","author":"Melero","year":"2024","journal-title":"Ann. Oncol. official J. Eur. Soc. Med. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12029-024-01038-2","article-title":"Atezolizumab and bevacizumab targeted-therapy in advanced hepatocellular carcinoma: a systematic review of cost-effectiveness analyses","volume":"55","author":"Mohammadnezhad","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jhep.2024.01.011","article-title":"Immunotherapy and transplantation for hepatocellular carcinoma","volume":"80","author":"Parissa","year":"2024"},{"key":"B40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1078-0432.CCR-23-2124","article-title":"FDA approval summary: tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma","volume":"30","author":"Patel","year":"2024","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"","journal-title":"Lancet London, Engl."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"","journal-title":"Lancet London, Engl."},{"key":"B43","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2024","journal-title":"J. hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"815575","DOI":"10.3389\/fimmu.2022.815575","article-title":"Knowledge mapping of immunotherapy for hepatocellular carcinoma: a bibliometric study","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"","journal-title":"J. Hematol. and Oncol."},{"key":"B47","first-page":"Jco2400645","article-title":"Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab","author":"Shen","year":"","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"12325","DOI":"10.1002\/cam4.5931","article-title":"The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"12","author":"Shimose","year":"2023","journal-title":"Cancer Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","article-title":"Biomarkers for immunotherapy of hepatocellular carcinoma","volume":"20","author":"Tim","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2478\/jtim-2024-0003","article-title":"A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma","volume":"12","author":"Wang","year":"2024","journal-title":"J. Transl. Int. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"7425","DOI":"10.3390\/ijerph19127425","article-title":"Mapping the global landscape of long-term care insurance research: a scientometric analysis","volume":"19","author":"Xia","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jhep.2024.02.009","article-title":"CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma","volume":"81","author":"Xie","year":"2024","journal-title":"J. hepatology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12885-024-12772-y","article-title":"Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000536376","article-title":"Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery","volume":"13","author":"Zeng","year":"2024","journal-title":"Liver Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"","journal-title":"Signal Transduct. Target. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e007366","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"","journal-title":"J. Immunother. Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1491404","DOI":"10.3389\/fonc.2024.1491404","article-title":"Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China","volume":"14","author":"Zhao","year":"2024","journal-title":"Front. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1200\/jco.2023.41.16_suppl.4126","article-title":"A phase II\/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: primary results of major pathologic response from phase II stage","volume":"41","author":"Zhou","year":"2023"},{"key":"B60","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/HEP.0000000000000776","article-title":"Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter, single-arm, phase 2 study","volume":"80","author":"Zhu","year":"2024","journal-title":"Hepatology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000514313","article-title":"Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1520055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:29:34Z","timestamp":1744003774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1520055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":61,"alternative-id":["10.3389\/fphar.2025.1520055"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1520055","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"article-number":"1520055"}}